CLNN - Clene Inc. Stock Price, Fair Value and News

$4.13+0.04 (+0.98%)

Delayed as of 21 Nov 2024, 09:54 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CLNN Price Action

Last 7 days

-15.1%

Last 30 days

-28.4%

Last 90 days

-22.8%

Trailing 12 Months

-55.5%

CLNN RSI Chart

CLNN Valuation

Market Cap

32.6M

Price/Earnings (Trailing)

-0.91

Price/Sales (Trailing)

77.52

EV/EBITDA

-0.58

Price/Free Cashflow

-1.38

CLNN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CLNN Fundamentals

CLNN Revenue

Revenue (TTM)

421.0K

Rev. Growth (Yr)

-19.44%

Rev. Growth (Qtr)

-4.4%

CLNN Earnings

Earnings (TTM)

-36.0M

Earnings Growth (Yr)

-230.27%

Earnings Growth (Qtr)

-17.7%

CLNN Profitability

Operating Margin

78.62%

EBT Margin

-8556.77%

Return on Equity

873.31%

Return on Assets

-114.11%

Free Cashflow Yield

-72.67%

CLNN Investor Care

Shares Dilution (1Y)

24.28%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	620.0K	442.0K	421.0K	0
2023	550.0K	784.0K	718.0K	654.0K
2022	540.0K	374.0K	438.0K	473.0K
2021	349.0K	541.0K	553.0K	723.0K
2020	0	0	0	206.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Clene Inc.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

CEO	Mr. Robert Etherington MBA
WEBSITE	https://clene.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	75

Clene Inc. Frequently Asked Questions

What is the ticker symbol for Clene Inc.? What does CLNN stand for in stocks?

CLNN is the stock ticker symbol of Clene Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Clene Inc. (CLNN)?

As of Wed Nov 20 2024, market cap of Clene Inc. is 32.64 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLNN stock?

You can check CLNN's fair value in chart for subscribers.

Is Clene Inc. a good stock to buy?

The fair value guage provides a quick view whether CLNN is over valued or under valued. Whether Clene Inc. is cheap or expensive depends on the assumptions which impact Clene Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLNN.

What is Clene Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, CLNN's PE ratio (Price to Earnings) is -0.91 and Price to Sales (PS) ratio is 77.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLNN PE ratio will change depending on the future growth rate expectations of investors.